Close Menu

NEW YORK (GenomeWeb) – Invivoscribe Technologies said today that it has released a new CE-marked IVD version of its LeukoStrat CDx FLT3 Mutation Assay, which was approved earlier this year by the US Food and Drug Administration.

The test is the first companion diagnostic for acute myeloid leukemia, and identifies both internal tandem duplication (ITD) and tyrosine kinase domain mutations, including large ITD alterations missed by other NGS-based assays.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.